Related Experiment Video

Updated: Jul 11, 2025

Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors
05:58

Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors

Published on: August 16, 2024

2.9K

Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment

Lingxi Jiang1, Yao Qi2, Lei Yang3

  • 1Sichuan Provincial Key Laboratory for Human Disease Gene Study and Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.

Asian Journal of Pharmaceutical Sciences
|November 3, 2023
PubMed

Insights

Transforming tumor microenvironments (TME) using small interfering RNA (siRNA) is crucial for cancer therapy. This review details siRNA

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • The tumor microenvironment (TME) often supports tumor growth, necessitating strategies for its transformation.
  • Small interfering RNA (siRNA) offers a powerful method for gene silencing via RNA interference (RNAi).
  • Current research focuses on siRNA delivery to target tumor cells and the TME.

Purpose of the Study:

  • To review the pharmacological actions of siRNA in remodeling the TME.
  • To discuss siRNA delivery strategies and combination therapies for TME modulation.
  • To present advancements in clinically investigated and commercialized siRNA delivery technologies.

Main Methods:

  • Literature review of siRNA pharmacology and delivery systems.
  • Analysis of current clinical and commercial siRNA delivery technologies.
  • Discussion of challenges in siRNA delivery: cargo protection, targeting, and release.

Main Results:

  • siRNA drugs show promise in silencing critical TME proteins.
  • Nanoparticle-based siRNA delivery is highlighted as a key strategy.
  • Significant advancements have been made in siRNA delivery technologies.

Conclusions:

  • siRNA holds significant potential for transforming the TME into an anti-tumoral state.
  • Overcoming delivery challenges is essential for effective siRNA-based cancer therapy.
  • Nanoparticle siRNA delivery is proposed as a future research focus for oncogene therapy.
Keywords:
Cancer therapyCo-deliverySmall interfering RNATumor microenvironmentsiRNA delivery

More Related Videos

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.7K
Preparation of Exosomes for siRNA Delivery to Cancer Cells09:59

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Published on: December 5, 2018

25.1K

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K